TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06701903: A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder Who Have Had Inadequat

Sponsor: Intra-Cellular Therapies, Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 570 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$6,772,800

Rescue Site Savings

+$4,482,000

Unlock Full NCT06701903 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06701903 Rescue Dossier →